Erudio Healtherudio.com
Drug
Imatinib trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying imatinib: GIMEMA ALL2820. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 4 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| GIMEMA ALL2820 NCT04722848 · Gruppo Italiano Malattie EMatologiche dell'Adulto | newly diagnosed adult Ph+ ALL | Phase 3 | 480 | 68 | Deep | Nov 20, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| ASC4FIRST NCT04971226 · Novartis Pharmaceuticals DeepView → | newly diagnosed Ph+ chronic-phase chronic myeloid leukemia | Phase 3 | Deep | View | |||
| NCT03589326 NCT03589326 · Takeda FocusedView → | Not given | Phase 3 | Focused | View | |||
| AALL2131 NCT06124157 · National Cancer Institute (NCI) FocusedView → | Ph+ or ABL-class Ph-like B-cell acute lymphoblastic leukemia | Phase 2 | Focused | View | |||
| SynerGIST-1st Line NCT07406633 · Kumquat Biosciences Inc. FocusedView → | Not given | Phase 2 | Focused | View | |||